B
CTIC

Bailard’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bailard’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,000
Closed -$89K – 846
2022
Q1 		$89K Buy
+19,000
New +$56.7K ﹤0.01% 699

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bailard's CTIC Position: Q2 2022 in Review

Bailard sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2022, closing a stake of 19,000 shares — an estimated $89K sold.

Bailard first reported a position in CTIC in Q1 2022 and held it in 1 quarter. The position peaked at $89K in Q1 2022. 119 funds tracked by Wall St. Rank hold CTIC as of Q2 2022.

  • Bailard reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bailard sold 19,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2022, an estimated $89K.
  • Bailard first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 1 quarter.
  • Bailard's CTI BioPharma Corp. (DE) Common Stock position peaked at $89K in Q1 2022.
  • 119 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.